Important Information for Your Healthcare Provider
You should talk with your healthcare provider prior to using this medication if you have:
Also, let your healthcare provider know if you are:
Make sure to tell your healthcare provider about all other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.
In clinical studies, icatibant was shown to reduce symptoms associated with HAE attacks. In these studies, people were given either icatibant or a placebo (an injection with no active ingredients) when they were experiencing an HAE attack. It took a median of 2 to 2.3 hours to reduce symptoms by 50 percent after icatibant was given, compared with 19.8 hours after a placebo was given.
HAE is caused by a defect in the gene that controls the production of a protein known as C1 inhibitor (C1-INH). C1-INH helps regulate complex reactions in the body, including reactions that control the production of a chemical known as bradykinin.
People with HAE either do not have enough C1-INH or have C1-INH that does not function properly. As a result, too much bradykinin is produced in the body. Bradykinin causes blood vessels to dilate (enlarge) and leak fluid into surrounding tissue. This is thought to be responsible for the swelling and pain associated with HAE attacks.
Icatibant is classified as a bradykinin inhibitor. It works by blocking the action of bradykinin, thereby relieving the symptoms of an HAE attack.